DE3711724A1 - System zum einwirken auf, insbesondere zerstoeren von viren - Google Patents

System zum einwirken auf, insbesondere zerstoeren von viren

Info

Publication number
DE3711724A1
DE3711724A1 DE19873711724 DE3711724A DE3711724A1 DE 3711724 A1 DE3711724 A1 DE 3711724A1 DE 19873711724 DE19873711724 DE 19873711724 DE 3711724 A DE3711724 A DE 3711724A DE 3711724 A1 DE3711724 A1 DE 3711724A1
Authority
DE
Germany
Prior art keywords
liposomes
genetic information
membrane
substance
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19873711724
Other languages
German (de)
English (en)
Other versions
DE3711724C2 (https=
Inventor
Harro Boerner
Joachim Giese
Peter Gerhardts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HARRO BOERNER MEDIZINISCHE KOM
Original Assignee
HARRO BOERNER MEDIZINISCHE KOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HARRO BOERNER MEDIZINISCHE KOM filed Critical HARRO BOERNER MEDIZINISCHE KOM
Priority to DE19873711724 priority Critical patent/DE3711724A1/de
Publication of DE3711724A1 publication Critical patent/DE3711724A1/de
Application granted granted Critical
Publication of DE3711724C2 publication Critical patent/DE3711724C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19873711724 1987-04-07 1987-04-07 System zum einwirken auf, insbesondere zerstoeren von viren Granted DE3711724A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19873711724 DE3711724A1 (de) 1987-04-07 1987-04-07 System zum einwirken auf, insbesondere zerstoeren von viren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873711724 DE3711724A1 (de) 1987-04-07 1987-04-07 System zum einwirken auf, insbesondere zerstoeren von viren

Publications (2)

Publication Number Publication Date
DE3711724A1 true DE3711724A1 (de) 1988-10-20
DE3711724C2 DE3711724C2 (https=) 1992-05-07

Family

ID=6325067

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19873711724 Granted DE3711724A1 (de) 1987-04-07 1987-04-07 System zum einwirken auf, insbesondere zerstoeren von viren

Country Status (1)

Country Link
DE (1) DE3711724A1 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0432693A1 (en) * 1989-12-11 1991-06-19 Sumitomo Chemical Company, Limited Liposomes cytotoxic to virus-infected cells
WO1992011846A1 (en) * 1991-01-07 1992-07-23 St George's Enterprises Limited Particulates
WO1993002709A1 (en) * 1991-07-31 1993-02-18 Microcarb Inc. Receptor conjugates for targeting drugs and other agents
WO1994016061A1 (en) * 1993-01-15 1994-07-21 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
WO1996022763A1 (es) * 1995-01-27 1996-08-01 PALOMINO MUÑOZ, Juan Manuel Liposoma para la destruccion del vih y de las celulas infectadas por el mismo
ES2088752A1 (es) * 1995-01-27 1996-08-16 Palomino Munoz Juan Manuel Liposoma para la destruccion del vih y de las celulas infectadas por el mismo.
EP0979655A1 (de) * 1998-08-01 2000-02-16 Boehringer Mannheim Gmbh Mittel zur Behandlung von durch RNA-Viren, wie beispielsweise HIV verursachten Infenktionen
EP0904066A4 (en) * 1996-05-03 2002-04-24 Roger S Cubicciotti DRUG COMPOSITIONS AND METHOD FOR ADMINISTERING DRUGS USING SYNTHETIC RECEPTORS
EP2747786A4 (en) * 2011-08-26 2015-03-04 Vecoy Nanomedicines Ltd FALLING FOR PATHOGENS AND SUBSTANCES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Die Pharmazie, 33.Jahrgang, Heft 8, August 1978, S. 493-496 *
J.S.SIM and K.G.MCCULLAGH in Approaches to Antiviral Agents Ed.M.R.Harnden, VCH Weinheim, 1985, S. 16-46 *
T.Y.SHEN in Directed Drug Delivery Ed.R.T. BORCHARDT et al., Humana Press, Clifton, New Jersey 1985, S. 231-245 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0432693A1 (en) * 1989-12-11 1991-06-19 Sumitomo Chemical Company, Limited Liposomes cytotoxic to virus-infected cells
WO1992011846A1 (en) * 1991-01-07 1992-07-23 St George's Enterprises Limited Particulates
WO1993002709A1 (en) * 1991-07-31 1993-02-18 Microcarb Inc. Receptor conjugates for targeting drugs and other agents
WO1994016061A1 (en) * 1993-01-15 1994-07-21 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
WO1996022763A1 (es) * 1995-01-27 1996-08-01 PALOMINO MUÑOZ, Juan Manuel Liposoma para la destruccion del vih y de las celulas infectadas por el mismo
ES2088752A1 (es) * 1995-01-27 1996-08-16 Palomino Munoz Juan Manuel Liposoma para la destruccion del vih y de las celulas infectadas por el mismo.
EP0904066A4 (en) * 1996-05-03 2002-04-24 Roger S Cubicciotti DRUG COMPOSITIONS AND METHOD FOR ADMINISTERING DRUGS USING SYNTHETIC RECEPTORS
EP0979655A1 (de) * 1998-08-01 2000-02-16 Boehringer Mannheim Gmbh Mittel zur Behandlung von durch RNA-Viren, wie beispielsweise HIV verursachten Infenktionen
EP2747786A4 (en) * 2011-08-26 2015-03-04 Vecoy Nanomedicines Ltd FALLING FOR PATHOGENS AND SUBSTANCES
AU2012303619B2 (en) * 2011-08-26 2017-01-19 Vecoy Nanomedicines Ltd. Pathogen and substance traps

Also Published As

Publication number Publication date
DE3711724C2 (https=) 1992-05-07

Similar Documents

Publication Publication Date Title
DE3711724A1 (de) System zum einwirken auf, insbesondere zerstoeren von viren
DE69022163T2 (de) Steriles erzeugnis und verfahren zur sterilisierung und zusammenbau dieses erzeugnisses.
DE69222303T2 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
BRISMAR Electrical properties of isolated demyelinated rat nerve fibres
DE69926725T2 (de) Eingekapselte ipg-streifen
DE2200054A1 (de) Implantierbare brennstoffzelle
Axelsson et al. Renal lesions in the rabbit after long-term exposure to cadmium
EP0819016A1 (de) Iontophoretisches transdermales system zum verabreichen von mindestens zwei substanzen
DE2655801A1 (de) Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen
EP3562574B1 (de) Verfahren zur separation von geladenen substanzen aus flüssigkeiten und deren wiedergewinnung
EP0859628B1 (de) Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
DE102010033105A1 (de) Massenspektrometrische Sepsisdiagnose ohne Blutkultur
EP1297119B9 (de) Verfahren zur einbringung von nukleinsäuren und anderen biologisch aktiven molekülen in den kern höherer eukaryontischer zellen mit hilfe elektrischen stroms
EP1303535A2 (de) Proteinkomplex als vehikel für oral verfügbare arzneimittel
EP2328623B2 (de) Verfahren zur verringerung der viralen und mikrobiellen belastung feststoffhaltiger aus dem pankreas von tieren gewonnener extrakte
EP3752128B1 (de) Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
EP1796649A2 (de) Nanotransportsystem mit dendritischer architektur
DE69110897T2 (de) Hemmung der viralen replikation.
EP3558336A1 (de) D-enantiomere peptide zur therapie von chronischem und neuropathetischem schmerz
Dudel Informationsvermittlung durch elektrische Erregung
DE69017338T2 (de) Blutreinigungsgerät und Verfahren um damit Blut zu reinigen.
DE2822731A1 (de) Vaccine zur immuntherapie neoplastischer erkrankungen
DE60123430T2 (de) Pharmazeutische zusammensetzung enthaltend träger für pharmakologisch aktive produkte wobei die träger auf vitamin e, papain und hyaluronidase basieren
DE4437023C1 (de) Verfahren zur Herstellung eines Bio-Sensors für elektromagnetische Strahlung
EP0274581B1 (de) Verfahren zur Herstellung von Liposomen

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee